Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Joel Randolph Hecht

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2277-4157; OpenAlex author ID A5001020016, A5112026771. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2505783↗
  2. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of C… Co-author DOI 10.1200/jco.22.02770↗
  3. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s10637-020-01000-6↗
  4. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  5. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing… Last author DOI 10.1186/s12885-020-07110-x↗
  6. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreat… Co-author DOI 10.1634/theoncologist.2017-0024↗
  7. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer… Co-author DOI 10.1016/j.gie.2011.10.007↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna C. Bendell · 4 shared papers, 2017–2021 · strength 0.39
  2. Zev A. Wainberg · 3 shared papers, 2017–2021 · strength 0.28
  3. Alexander Starodub · 1 shared paper, 2026 · strength 0.23
  4. Wungki Park · 1 shared paper, 2026 · strength 0.23
  5. Nilofer Saba Azad · 1 shared paper, 2026 · strength 0.23
  6. Brian Matthew Wolpin · 1 shared paper, 2026 · strength 0.23
  7. Minal A. Barve · 1 shared paper, 2026 · strength 0.23
  8. David S. Hong · 1 shared paper, 2026 · strength 0.23
  9. Ignacio Garrido‐Laguna · 1 shared paper, 2026 · strength 0.23
  10. Alexander I. Spira · 1 shared paper, 2026 · strength 0.23
  11. Kyaw Lwin Aung · 1 shared paper, 2026 · strength 0.23
  12. Andrés Jesús Muñoz Martín · 2 shared papers, 2020–2021 · strength 0.21
  13. Sara Lonardi · 2 shared papers, 2020–2021 · strength 0.21
  14. Baek‐Yeol Ryoo · 2 shared papers, 2020–2021 · strength 0.21
  15. Arié Figer · 1 shared paper, 2023 · strength 0.15
  16. David Goldstein · 1 shared paper, 2023 · strength 0.15
  17. Wendy R. Parulekar · 1 shared paper, 2023 · strength 0.15
  18. Robert A. Wolff · 1 shared paper, 2023 · strength 0.15
  19. Steve Gallinger · 1 shared paper, 2023 · strength 0.15
  20. Malcolm J. Moore · 1 shared paper, 2023 · strength 0.15
  21. Milind M. Javle · 2 shared papers, 2012–2021 · strength 0.12
  22. Ivelina Gueorguieva · 1 shared paper, 2021 · strength 0.11
  23. Joon Oh Park · 1 shared paper, 2021 · strength 0.11
  24. Richard Greil · 1 shared paper, 2021 · strength 0.11
  25. Charles D. Lopez · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.